GEM evolution comes from continuous commitment to research and effort to improve our products, to demonstrate the efficiency and quality of them, not only with the contribution of our professional experts, but also with clinical studies on the most innovative products.
Innovation is part of GEM’s DNA as shown by the important results and solutions developed and achieved year after year in response to our clients’ needs, working together, testing at site and analyzing results, but progressively, we try to anticipate clients’ needs and future technological challenges, working at introducing innovative solutions independently.
GEM development is never complete and we therefore constantly strive towards the improvement of our devices, systems and protocol of uses.


GLUBREAST: Seroma Prevention after axillary dissection for breast cancer using a cyanoacrylate based sealing glue: Prospective Randomized Trial

The aim of this trial is to confirm and verify the effectiveness of Glubran® 2, in preventing and/or reducing seroma formation in patients after total or partial mastectomy with axillary clearance.
A recent study demonstrates that Glubran® 2 may contribute to the reduction of seromas produced after mastectomy and subsequently decrease the duration of postoperative drainage and the frequency of seroma aspirations. However, because the pathogenesis of seroma formation is multifaceted and complex, further research is required to confirm the results of this study . At the light of what mentioned we have thought to perform a prospective randomized trial with the aim to confirm and verify again the effectiveness of using the above mentioned surgical synthetic sealant ( [NBCA+ MS]: Glubran® 2) applied in a nebulized way, to prevent or reduce seroma formation following axillary lymphadenectomy for breast cancer.


ANASTOSEAL: “Seal and strengthen intestinal anastomosis in colorectal cancer surgery”: Prospective observational study.

The anastomotic leak prevention can bring benefits to the patient and the health system. An effective prevention is based on the knowledge of the repair mechanisms that lead to the consolidation of intestinal anastomosis.
The use of intraoperative procedures to prevent dehiscence of the anastomosis, such as the addition of additional manual points, the mechanical suture and / or patches of collagen (reinforcement so called also buttressing) or sealants (fibrin or cyanoacrylate glues, such as Glubran® 2) is the rationale that led to the design of this study. Although today we have technologically advanced mechanical staplers, it is crucial to prevent anastomotic dehiscence. At the moment experimental results show that Glubran® 2 is a suitable potential “reinforcement” of intestinal anastomoses both manual and linear intracorporeal. Glubran 2 applied after the packaging of the mechanical anastomosis, polymerizes in a short time closing the micro spaces of the suture line between one point and the other, expressing an adhesive, hemostatic and sealant action on the tissues, creating an effective antiseptic barrier against the most common infectious agents or pathogens.

The aim of the study is to evaluate the incidence of anastomotic fistula after application of reinforcement with the modified cyanoacrylate sealant, within the first 10 postoperative days and compare the results with historical literature data in patients in whom the sealing reinforcement application was not used.